Kurzfassung

A phase II, randomized, double-blind, placebo-controlled study of Tiragolumab in combination with Atezolizumab plus Pemetrexed and Carboplatin/Cisplatin versus Pembrolizumab plus Pemetrexed and Carboplatin/Cisplatin in patients with previously untreated advanced non-squamous non small cell lung cancer